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Abstract
Background: RhoA and RhoC have been proved to be over-expressed in many solid cancers, including colorectal
cancer. The reduction of RhoA and RhoC expression by RNA interference (RNAi) resulted growth inhibition of
cancer cells. The present study was to evaluate the effect of silencing of RhoA and RhoC expression by RNAi on
growth of human colorectal carcinoma (CRC) in tumor-bearing nude mice in vivo.
Methods: To establish HCT116 cell transplantable model, the nude mice were subcutaneously inoculated with
1.0 × 10
7 HCT116 cells and kept growing till the tumor xenografts reached 5-7 mm in diameter. Then the mice
were randomly assigned to three groups(seven mice in each group): (1) normal saline(NS) group, (2)replication-
defective recombinant adenovirus carrying the negative control shRNA (Ad-HK) group and (3)replication-defective
recombinant adenovirus carrying the 4-tandem linked RhoA and RhoC shRNAs (Ad-RhoA-RhoC) group. Ad-HK
(4 × 10
8 pfu, 30 ul/mouse), Ad-RhoA-RhoC (4 × 10
8 pfu, 30 ul/mouse) or PBS (30 ul/mouse) was injected
intratumorally four times once every other day. The weight and volumes of tumor xenografts were recorded. The
levels of RhoA and RhoC mRNA transcripts and proteins in tumor xenografts were detected by reverse quantitative
transcription polymerase chain reaction (QRT-PCR) and immunohistochemical staining respectively. The terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was used to detect the death of cells.
Results: The xenografts in mice could be seen at 5th day from the implantation of HCT116 cells and all had
reached 5-7 mm in size at 9th day. After injection intratumorally, the growth speed of tumor xenografts in Ad-
RhoA-RhoC group was significantly delayed compared with those in NS and Ad-HK group(P < 0.05). The results of
QRT-PCR showed that mRNA levels of RhoA and RhoC reduced more in Ad-RhoA-RhoC group than those in NS
and Ad-HK group. The relative RhoA and RhoC mRNA transcripts were decreased to 48% and 43% respectively
(P < 0.05). Immunohistochemical analyses of tumor xenograft sections also revealed the decreased RhoA and RhoC
expression in Ad-RhoA-RhoC group. TUNEL assay also showed higher death of tumor xenograft tissue cells in
Ad-RhoA-RhoC group.
Conclusion: Recombinant adenovirus mediated RhoA and RhoC shRNA in tandem linked expression may inhibit
the growth of human colorectal tumor xenografts in vivo. These results indicate that RhoA and RhoC might be
potential targets for gene therapy in colorectal cancer.
Background
Colorectal carcinoma (CRC) is one of the most common
cancers and accounts for about 10% of all new cancer
cases and cancer deaths in the US in recent two years
[1,2]. And the incidence is increasing rapidly in
developing countries including China[3]. Despite surgi-
cal resection coupled with systemic chemotherapy,
about half of newly diagnosed colorectal cancer patients
will still die of this disease due to tumor recurrence and
metastasis[4]. The initiation, development, local invasion
and distal metastasis for tumor are regulated by multiple
genes, whose expressions are determined by either inter-
nal or external factors. Therefore, elucidation of those
factors and the pattern of their expression may help to
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tasis of colorectal carcinoma.
RhoA and RhoC have been known to be involved in
regulating multiple aspects of cell migration, affecting
the different components of the cytoskeleton as well as
cell-substrate adhesion and possibly matrix remodeling
[5,6]. RhoA and RhoC proteins have implicated them as
important factors in promoting the uncontrolled prolif-
eration and invasive and metastatic properties of cancer
cells[7], however, it is poorly understood how they are
activated in cancer cells. Studies have demonstrated that
the over-expression of RhoA and RhoC in most solid
malignancies including colorectal cancer is more fre-
quently than in normal tissue[8-13]. Therefore, specific
inhibiting the functions of RhoA and RhoC is predicted
to be of great therapeutic benefits.
Previous studies have shown that interfering the
expression of RhoA and RhoC using small interfering
RNA (siRNA) approaches inhibited the proliferation and
invasion of some cancer cells[14-17]. Our previous stu-
dies have also demonstrated that the over-expression of
RhoA and RhoC occured in colorectal cancer tissues
from Chinese patients and RhoA and RhoC shRNAs in
tandem linked expression could markedly inhibit the
invasion and migration potentials of colorectal cancer
cells[18,19]. In this study, we evaluated the inhibitory
efficacy of RhoA and RhoC shRNAs in tandem linked
expression in vivo. Our results showed that the recom-
binant adenovirus-mediated siRNA inhibited the growth
of colorectal cancer cell grafts implanted in nude mice,
which suggests that RhoA and RhoC might serve as
potential targets for gene therapy in colorectal cancer
and such shRNA-induced in tandem linked RNA inter-
ference might be more effective in targeting multiple
genes in cancer therapy.
Methods
Experimental Animals
Twenty-one athymic nude male BALBC/c mice(4-5
weeks old, 15-18 g), obtained from Beijing Experimental
Animal Center, China, were maintained in a specific
pathogen free, temperature-controlled isolation condi-
tions, fed with sterilized food and autoclaved water Ani-
mal breeding, care and experiment procedures were
approved by ethical and humane committee of Affiliated
Hospital of Qingdao University Medical College and
carried out strictly in accordance with the related ethical
regulations.
Cell Line and Cell Culture
The human colon cancer cell line HCT116 was pur-
chased from China Centre for Type Culture Collection.
The cells were grown in McCoy’s 5A medium, Modified
(Sigma), supplemented with 10% of fetal bovine serum
(Hyclone, USA) at 37°C in a humidified atmosphere of
5% CO2. The cells were always detached using 0.25%
trypsin and 0.02% ethylene diamine tetra acetic acid
(EDTA).
In vivo Tumor Xenograft Model
To establish the transplantable model, the human colon
cancer cells in logarithm growth phrase were harvested
and washed twice with PBS. 1.0 × 10
7 cells in 200 uL of
PBS with a viability of >95% tested by staining with try-
p a nb l u ew e r ei n j e c t e ds u b c u t a n e o u s l yi n t ot h er i g h t
flank of each mouse. All nude mice were observed to
generate tumors for up to 9 days after the injection.
When tumor nodules reached 5-7 mm in diameter,
tumor model was successfully established and mice
were randomly assigned to the following 3 groups(seven
mice in each group): (1)normal saline(NS) group, (2)
Ad-HK group and (3) Ad-RhoA-RhoC group. Ad-HK
(4 × 10
8 pfu, 30 ul/mouse), Ad-RhoA-RhoC (4 × 10
8
pfu, 30 ul/mouse) or PBS (30 ul/mouse) was injected
intratumorally at several points four times once every
other day, with the accumulated doses of 1.6 × 10
9 pfu.
The tumor sizes were determined every other day by
external measurements with a vernier caliper and calcu-
lated the tumor volume and plotted against time [The
tumor volume = ab
2/ 2 ,w h e r eaa n dba r et h el a r g e r
and smaller diameter, respectively]. Ten days after the
final injection, the tumors were dissected and their
weights and volumes were measured. Then, each har-
vested tumor was divided into two parts, one was used
for detecting the mRNA expression of the related genes
and the other was used for immunohistochemical analy-
sis as described below.
Quantitative RT-PCR for RhoA and RhoC in Xenograft
Tumors
Total RNA was extracted from -80°C freezed trans-
planted tumor samples, dissected from nude mice, using
Trizol reagent(Invitrogen, USA) and reverse transcripted
into cDNA using the PrimeScript RT-PCR kit (TaKaRa
Bio Inc., Shiga, Japan), according to the manufacturer’s
instructions. To assess the RhoA and RhoC gene expres-
sion, we used real-time fluorescence quantitative PCR
analysis based on the TaqMan probe method. The
probe contains 6-carboxy-fluorescein (FAM) as a fluor-
escent reporter dye, and 6-carboxytetramethyl-rhoda-
mine (TAMRA) as a quencher for its emission
spectrum. The primers, TaqMan probes and PCR para-
meters were performed same as reported previously by
us [18,19].
Histopathological and Immunohistochemical Study
Half of the implanted tumor tissues which were dis-
sected from nude mice were fixed in 10% formalin,
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sections for hematoxylin-eosin and immunohistochem-
ical staining. Briefly, tissue sections were baked, deparaf-
finized and microwaved at 98°C for 10 minutes in
citrate buffer (0.01 M citric acid, pH6.0). After blocking
the endogenous peroxidase by immersed the sections in
3% H2O2, the sections were incubated with primary
antibodies directing against human RhoA (sc-32039,
1:50; Santa Cruz) and RhoC (sc-12116, 1:50; Santa
Cruz). Expression of RhoA or RhoC protein in tissue
sections was detected with Anti-goat IgG/HRP Detec-
tion Kit(PV-6003; Zhongshan Biotechnology Limited
Company, Beijing, China). The tissue sections were then
counterstained with hematoxylin.
Terminal Deoxynucleotidyl Transferase-mediated dUTP
Nick End-labeling (TUNEL) Assay
Assessment of cell death was performed by TUNEL
method using an in situ cell death detection kit conju-
gated with horse-radish peroxidase (POD) (Roche
Applied Science, Indianapolis, IN, USA), according to
the manufacturer’s instructions. Five equal-sized fields
in tissue sections were randomly chosen and analyzed
under the Leica DMI 4000B(Leica, Germany) light
microscope. Density was evaluated in each positive
staining field, yielding the density of dead cells (cell
death index).
Statistical Analysis
All data were shown by mean ± SD. Statistical analyses
were performed using SPSS statistical software (SPSS
Inc., Chicago, Illinois). Differences between two groups
were assessed using a t test. A P value less than 0.05
was considered statistically significant.
Results
Ad-RhoA-RhoC-siRNA Inhibits Tumor Development in
Nude Mice
Tumors in the nude mice could be seen at 5th day from
the implantation of HCT116 cells and all tumors had
reached 5-7 mm in size at 9th day. The successful rate
of tumor implantation was 100%(Figure 1). After intra-
tumorally injection, the growth speed of tumors in the
three group was quite different. As shown in figure 2,
the tumors in NS and Ad-HK group grew rapidly. In
contrast, tumors in Ad-RhoA-RhoC group were signifi-
cantly delayed. The dissected tumors in the NS and Ad-
HK group had volumes of (699.62 ± 190.56)mm
3 and
(678.81 ± 155.39)mm
3, which were 5.05 ± 0.48-fold and
4.58 ± 0.94-fold larger than the starting volume, whereas
in the Ad-RhoA-RhoC group, the tumors had a volume
of (441.38 ± 63.03)mm
3, increased only 2.38 ± 0.56-fold
(Figure 3). Tumor growth delay was statistically signifi-
cant (P < 0.05). In addition, the mean tumor weight in
NS, Ad-HK and Ad-RhoA-RhoC group was (0.75 ±
0.22) g, (0.78 ± 0.22) g and (0.36 ± 0.13) g, respectively.
These data demonstrated that injection of Ad-RhoA-
RhoC was able to slow down the growth of HCT116-
derived xenografts.
Effect of Ad-RhoA-RhoC on Expression of RhoA and RhoC
mRNA in Implanted Tumors
PCR product electrophoresis analysis clearly demon-
strated a single RhoA band at 158 bp, RhoC band at
136 bp and GAPDH band at 150 bp, which were the
expected sizes (figure not shown). Real-time fluores-
cence quantitative PCR analyses showed the mRNA
levels of RhoA and RhoC were significant decreased in
Ad-RhoA-RhoC group compared with the NS group (P
< 0.05, Table 1). The relative RhoA and RhoC mRNA
expression in Ad-RhoA-RhoC group to the NS group
were only about 48% and 43%, respectively. However,
there was no significant difference between NS group
and Ad-HK group (P > 0.05). The results showed that
the RhoA and RhoC genes were specifically silenced in
Ad-RhoA-RhoC group.
Immunohistochemical Staining for RhoA and RhoC in
Xenograft Tumor
The results of hematoxylin-eosin staining for the patho-
logical changes in tumors were observed under light
microscopy (Figure 4). Many necrotic regions were
found in the tumors in all the three groups. But in the
Ad-RhoA-RhoC group, cancer cells showed intense
positive staining with smaller cell sizes and contracted
Figure 1 Tumor-bearing nude mice with 100% of tumor
implantation rate.
Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:123
http://www.jeccr.com/content/29/1/123
Page 3 of 7nucleus. Immunohistochemical staining results for RhoA
and RhoC w e r es h o w ni nF i g u r e5 .I nA d - R h o A - R h o C
group, the cancer cells of tumor tissues stained very
weakly for RhoA and RhoC,i nc o m p a r i s o nw i t hN S
group and Ad-HK group. Through quantitative data
analysis using the Leica Qwin image processing and
analysis software (Leica Imaging Solution Lid., Version
3.3.1, Cambridge, UK), the integrated optical density
(IOD) values of tumor tissues of NS group, Ad-HK
group and Ad-RhoA-RhoC group were 148.02 ± 9.62,
133.44 ± 7.24, 73.51 ± 7.06 for RhoA and 134.53 ± 4.51,
130.74 ± 3.78, 76.23 ± 2.17 for RhoC, respectively.
(Figure 5).
Death Assay of Cells of Tumor Tissues by TUNEL
As shown in Figure 6, cancer cells of tumor tissues in
Ad-RhoA-RhoC group demonstrated extensive cell
death, whereas in NS group and Ad-HK group resulted
Figure 2 Growth curve of subcutaneous implanted tumors in nude mice treated with NS, Ad-HK, or Ad-RhoA-RhoC. Tumor volume is
plotted against time elapsed. A significant delay in tumor growth is seen in the group treated with Ad-RhoA-RhoC. Data are presented as
means±SD (n = 7). * P < .05, from this point onwards.
Figure 3 Comparison of the size of harvested implanted tumors in nude mice treated with NS, Ad-HK, or Ad-RhoA-RhoC.A :f r e s h
anatomized B: formalin-fixed.
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induction of cell death by RhoA-RhoC siRNA treatment
is highly specific.
Discussion
It has been known that the initiation, development,
invasion and metastasis for colorectal carcinoma are
controlled by many different genes and various signal
transduction pathways and involved in many important
biological processes. RhoA and RhoC,t h eR h o - r e l a t e d
members, have been identified to be involved in diverse
signal transduction pathways that control essential cellu-
lar functions such as cell growth, cell differentiation,
cytoskeletal organization, intracellular vesicle transport
and secretion[20]. Despite the high homology of RhoA
and RhoC, RhoA has been shown to regulate the activ-
ities of multiple transcription factors, most of which are
implicated in the cancer progression [21] by modulating
cancer cell adhesion, contraction, movement, release of
cellular adhesion, degradation of extra-cellular matrix,
and invasion into blood or lymph vessels [22,23], while
RhoC contributes to tumor development, especially to
invasion and metastasis of cancer cells [24,25]. But the
molecular mechanisms were still unclear.
Previous studies including ours have demonstrated
that the overexpression or up-regulation of RhoA and
RhoC in colorectal cancer was significantly higher than
those in the corresponding paratumor and normal tis-
sues, suggesting the involvement of these two genes in
the onset, development and disease progression. of
colorectal carcinoma [11,12,18,26]. Moreover, some
reports showed that down-regulating the expression of
RhoA and RhoC using small interfering RNA (siRNA)
approaches may inhibit the proliferation and invasive-
ness of cancer cells [14-17,19,27]. Therefore, specific
inhibiting the abnormal expression of RhoA and RhoC
may be an effective strategy for CRC therapy.
Now, RNA interference has become widely used in
vivo knockdown of genes in cancer therapy. However,
safe, feasible and effective delivery methods in vivo are
still of critical importance[28]. Viral vectors do possess
significant advantages in cancer therapy in vivo and
gene therapy with intratumorally injected recombinant
adenoviral vectors mediating sequence-specific gene
silence offers the potential to restrict therapeutic gene
expression in the tumor. Thus, the use of RNAi in a
stable viral vector system, such as the adenovirus, is a
highly desirable strategy for stable gene knockdown in
anticancer gene therapy[29-31].
Our previous in vitro data have demonstrated that our
recombinant adenovirus mediated RhoA and RhoC
shRNA in tandem linked expression successfully inhibits
the expression of RhoA and RhoC in CRC cell line
HCT116 and proliferation of CRC cells. On the basis of
in vitro results, the present study was aimed to deter-
mine whether the recombinant adenovirus mediated 4-
tandem linked shRNA construct targeting RhoA and
RhoC genes may inhibit the growth of human colorectal
cancer cell graft implanted in nude mice in vivo.O u r
results indicated that the growth speed of the implanted
tumors in NS, Ad-HK and Ad-RhoA-RhoC groups was
quite different after intratumoral injection of NS, Ad-
HK and Ad-RhoA-RhoC respectively. The tumor weight
and the tumor volume were significantly declined in
Ad-RhoA-RhoC group. RT-PCR and immunohistochem-
istry results showed that the mRNA and protein expres-
sions of RhoA and RhoC were markedly decreased in
Ad-RhoA-RhoC group. The TUNEL study also disclosed
that increased dead cells in this group compared with
Table 1 The level of RhoA and RhoC transcripts in
implanted tumors in different groups
Group RhoA RhoC
ΔΔCT Rel. to NS
a ΔΔCT Rel. to NS
a
NS 0 ± 0.22 1 (0.86-1.16) 0 ± 0.26 1 (0.84-1.20)
Ad-HK 0.09 ± 0.18 0.94(0.83-1.06) 0.12 ± 0.15 0.92(0.83-1.02)
Ad-RhoA-RhoC 1.05 ± 0.27 0.48(0.40-0.58) 1.23 ± 0.14 0.43(0.39-0.47)
a. Data are expressed as the mean 2
-ΔΔCT (range).
Figure 4 Tumor tissues in nude mice in different treated groups (HE, ×200) A: NS group; B: Ad-HK group; C: Ad-RhoA-RhoC group.
Tumor cells were intensely stained with hematoxylin and showed smaller sizes. Necrotic regions were mainly eosin stained.
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that the recombinant adenovirus mediated RhoA and
RhoC shRNA in tandem linked expression could inhibit
the growth of tumors in CRC-bearing nude mice.
To our knowledge, this is the first study that 4-tan-
d e ml i n k e ds h R N Ac o n s t r u c tt a r g e t i n gRhoA and RhoC
genes can inhibit the growth of colorectal tumors in
vitro and in vivo. RhoA and RhoC g e n em a yb ep r o m i s -
ing molecular targets for colorectal cancer gene therapy.
Although, there are three mice in NS and Ad-HK group
died one or two days before the harvest day in our
study, we think this is irrelative to the adenovirus
Figure 5 Immunohistochemistry reaction for RhoA and RhoC protein in implanted tumor tissues of nude mice in different treated
groups (RhoA, ×400, RhoC, ×200). Fig 5 also showed the integrated optical density (IOD) values of the implanted tumor tissues. A: NS group;
B: Ad-HK group; C: Ad-RhoA-RhoC group. The positive cells were stained brown, using antibodies to RhoA or RhoC.
Figure 6 Cell death in implanted tumor tissues. Cell death was detected by TUNEL assay in implanted tumors treated with NS(A), Ad-HK(B),
or Ad-RhoA-RhoC(C and D). Original magnification, ×200. The nuclei of positive cell were stained brown.
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All the data we observed about the adenovirus applica-
tion shows no any serious side effects(data not shown),
which means that adenoviral vector-based delivery of in
tandem linked shRNAs is a safe and efficient therapeutic
approach. There weren’t any differences such as body
weight, implanted tumor weight, etc. between NS and
Ad-HK group. However, we have kept doing research
work on comparing the inhibitory effects of multiple
shRNAs expression vectors with single shRNA expres-
sion vector. And further research work should be done
to examine the downstream effectors of RhoA and
RhoC; such as ROCK-I and ROCK-II, being most asso-
ciated with metastasis and progress in cancer, which will
be benefit for exploring the possible molecular mechan-
isms of RhoA and RhoC in tumor inhibition.
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